SOURCE-LINKED STUDY SUMMARY
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Abstract summarizedQuality not appraised
- What was studied
- Randomized, double-blind phase 3 trial compared weekly retatrutide with placebo for 40 weeks. The primary outcome was HbA1c, a blood-sugar marker; weight change was secondary.
- Who / model studied
- 537 adults with type 2 diabetes inadequately controlled by diet and exercise alone were randomized.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- HbA1c fell 1·69–1·94 percentage points across retatrutide groups versus 0·81 with placebo. Weight fell 11·5–15·3% versus 2·6%. Gastrointestinal events were generally mild or moderate; adverse-event discontinuations were 2–5% versus 0%. No severe low blood sugar occurred. Two deaths were judged unrelated to treatment.
- Limitations & context
- No author-stated limitations were available in the abstract. The comparison covered 40 weeks against placebo, not an active drug.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(26)00967-0